EyeGate Pharmaceuticals - OBG shows benefits in pilot dry eye study
EyeGate recently delivered positive top-line data in a 20-patient trial studying the firm’s lead product, Ocular Bandage Gel (OBG), in patients with moderate dry eye disease (DED). Compared to the positive control, Allergan’s Refresh Preservative-Free OTC lubricant, OBG eye drops showed improvements in central corneal region staining, high order ocular aberrations (HOA) and best corrected visual acuity (BCVA). These results are indicative of therapeutic benefits and EyeGate is gearing to potentially launch a pivotal trial programme in H220.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.